<DOC>
	<DOCNO>NCT02810730</DOCNO>
	<brief_summary>Pancreatic adenocarcinoma 4th leading cause cancer USA . Its incidence increase France Europe , whereas cancer decrease Europe . Moreover , seriousness still high , mortality rate high average incidence . The aim PAPAFA study ass prevalence pancreatic anomaly reveal thanks image , patient 1st degree pancreatic adenocarcinoma familial history . This could allow detection lesion less 10 mm long , improve dark prognostic pathology .</brief_summary>
	<brief_title>Prevalence Pancreatic Anomalies Patients With 1st Degree Familial History Pancreatic Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<criteria>patient 1st degree familial history pancreas adenocarcinoma patient old 40 patient whose life expectancy &gt; 3 month inform consent form sign patient insured French social security system contraindication MRI ( pacemaker , implant metallic material , medical history allergy contrast agent , endstage renal failure , pregnancy , claustrophobia ) contraindication anesthesia echo endoscopy 1st degree family history 2 pancreas adenocarinomas medical history allergy benzylic alcool contraindication dimeglumine gadobenate pregnant breastfeed woman , accord question subjets n't legal capacity consent</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>pancreas</keyword>
	<keyword>adenocarcinoma</keyword>
</DOC>